The role of the genes of the dopaminergic system in the development of antipsychotic-induced hyperprolactinaemia in patients with schizophrenia
Hyperprolactinemia is a common side effect of antipsychotic treatment of patients with schizophrenia. The present study aimed to investigate the associations of polymorphic variants genes of dopamine receptors and transporter (DRD1, DRD2, DRD3, SLC6A3) with hyperprolactinemia. The study involved 445 patients with schizophrenia receiving antipsychotic medication. Were revealed statistically significant results for polymorphisms of genes DRD1 (rs936461), DRD2 (rs6277) and SLC6A3 (rs2550956), demonstrating their role in the pathogenesis of antipsychotic-induced hyperprolactinemia.